Clinical trials: Hydroxychloroquine
Myositis Associated Interstitial Lund Disease (MA-ILD)
Myositis Interstitial Lung Disease Nintedanib Trial
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD).
- Trial name
- MINT (NCT05799755)
- Testing
- Nintedanib, Standard of Care
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Rohit Aggarwal, MD
Lung Cancer
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, carboplatin, and paclitaxel and work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00728845
- Testing
- bevacizumab, carboplatin, hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Lymphangioleiomyomatosis
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Specific Aim 1: To investigate whether, in Lymphangioleiomyomatosis (LAM) patients, the combination of sirolimus and hydroxychloroquine is safe and well tolerated Specific Aim 2: To investigate whether, in LAM patients, 6 months…
- Trial name
- SAIL (NCT01687179)
- Testing
- "Sirolimus" and "Hydroxychloroquine" 200 mg, "Sirolimus" and "Hydroxychloroquine" 400 mg
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital
Sarcoma
A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma
Determine the objective response rate in sarcoma patients treated with hydroxychloroquine and sirolimus.
- Trial name
- NCT01842594
- Testing
- Sirolimus and hydroxychloroquine
- Where
- Taiwan
- Volunteers
- 13 people
- Sponsor
- Shin Kong Wu Ho-Su Memorial Hospital
Chronic Pancreatitis, Insulin Dependent Diabetes
Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT
This will be a pilot, 12-month phase II, open label, randomized, two-arm, single-blinded, placebo-controlled, parallel clinical trial of individuals undergoing TPAIT (Total Pancreatectomy and Autologous Islet Transplantation) for…
- Trial name
- NCT03283566
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
Covid-19
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease
Two recent studies have suggested that in patients with Covid19, treatment with hydroxychloroquine may shorten the duration of symptoms and improve viral clearance, an effect that appears most pronounced when combined with…
- Trial name
- NCT04358081
- Testing
- HCQ, HCQ+AZT
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C
Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C
Proof-of Concept, Open-Label, Two-Stage Study without Direct Individual Benefit The proposed study design consists of two treatment periods and one treatment arm.
- Trial name
- NCT01833845
- Testing
- Ribavirin, Hydroxychloroquine
- Where
- 2 sites in France
- Volunteers
- 4 people
- Sponsor
- BioLineRx, Ltd.
Rheumatoid Arthritis
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
Primary Objective: To assess the effect of sarilumab in combination with conventional synthetic Disease-Modifying Anti-Rheumatic Drug (csDMARD) and/or monotherapy on participant-reported impact of disease, using the rheumatoid…
- Trial name
- SariPRO (NCT03449758)
- Testing
- SARILUMAB, Azathioprine, Chloroquine
- Where
- 33 sites in France
- Volunteers
- 84 people
- Sponsor
- Sanofi
Congenital Heart Block, Neonatal Lupus
Preventive Approach to Congenital Heart Block With Hydroxychloroquine
Women with antibodies to proteins called SSA/Ro and or SSB/La face a 2% chance of having a child with a life threatening heart condition regardless of whether they have very active lupus, are in remission, or have only vague…
- Conditions
- Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block
- Trial name
- PATCH (NCT01379573)
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- NYU Langone Health
SARS-CoV Infection, Covid19
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
New outpatient treatments for COVID-19 are urgently needed. There is some evidence that a combination of three medications currently used to treat other viral infections could be effective in fighting this new virus.
- Trial name
- TriACT (NCT04605588)
- Testing
- Nitazoxanide, Ribavirin, Hydroxychloroquine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rutgers, The State University of New Jersey
Rheumatoid Arthritis
A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
This 2-arm study assessed the safety and efficacy of tocilizumab versus placebo, both in combination with disease modifying antirheumatic drugs (DMARDs), in regard to reduction in signs and symptoms, in patients with moderate to…
- Trial name
- ROSE (NCT00531817)
- Testing
- Tocilizumab, Permitted DMARDs
- Where
- 157 sites in United States, Puerto Rico
- Volunteers
- 619 people
- Sponsor
- Hoffmann-La Roche
Interstitial Lung Disease, Diffuse Parenchymal Lung Disease
Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)
This is an exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.
- Conditions
- Interstitial Lung Disease, Diffuse Parenchymal Lung Disease, Children´s Interstitial Lung Disease
- Trial name
- HCQ-chILD-EU (NCT02615938)
- Testing
- Hydroxychloroquine sulfate
- Where
- 9 sites in Germany
- Volunteers
- 35 people
- Sponsor
- Matthias Griese